Sebbene la figura del farmacista sia ormai da anni inserita all’interno dei team multidisciplinari, ora cominciamo a disporre di dati scientifici consistenti che confermino il valore aggiunto di tale presenza.
L'AIFA ha dato il via libera alla rimborsabilità della prima terapia a base di cellule CAR-T disponibile in Italia che potrà essere prescritta secondo le indicazioni EMA e utilizzata presso i centri specialistici.
Celestino Bufarini, Responsabile U.O.C. Farmacia Ospedaliera AREA VASTA 1 ASUR Marche, descrivendo le sue differenti esperienze lavorative evidenzia le molte sfaccettature di una professione in un cui l’innovazione tecnologica e l'importante ruolo di counseling del farmacista devono necessariamente viaggiare di pari passo.
Centralizzazione e informatizzazione dei processi, distribuzione diretta dei farmaci. Con Andrea Marco Machiavelli, Direttore Servizio di Farmacia Ospedaliera, scopriamo l'Azienda Socio-Sanitaria Territoriale di Cremona
Background and objectives: In economic evaluations in oncology, adjusted survival should be generated if imbalances in prognostic/predictive factors across treatment arms are present. To date, no formal guidance has been developed regarding how such adjustments should be made. We compared various covariate-adjusted survival modeling approaches, as applied to the ENDEAVOR trial in multiple myeloma that assessed carfilzomib plus dexamethasone (Cd)
Lessons learned: The combination of ofatumumab and bendamustine in elderly patients with diffuse large B-cell lymphoma demonstrated modest efficacy compared with standard of care.The poor response may have been due to patient age and the high rate of treatment discontinuation.
Background: This phase II trial evaluated the efficacy of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were
Background: With the ever-increasing complexity of cancer treatments, oncology medication patient education is becoming a progressively important component of cancer care. Despite this, cancer patients frequently report that they receive inadequate information and feel that their education needs have not been met.
Objective: To explore patients' perspectives of optimal oncology medication education across Nova Scotia.
Methods: This was a descriptive survey of
Background: Patients with advanced cancer commonly experience pain and it is least controlled in community settings. Community pharmacists in the UK already offer medicines optimisation consultations although not for this patient group.
Objective: To determine whether medicines consultations for patients with advanced cancer pain are feasible and acceptable. SettingCommunity-dwelling patients with advanced cancer pain were recruited from primary, secondary and tertiary care
This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients.
Trial-based evaluations and decision analytic modelling represent the two main vehicles for CEA. The costs to consider will depend on the